General Notices

• Notice to Extend the Response Date for NOT-AT-20-013 "Request for Information: Soliciting Input for the National Center for Complementary and Integrative Healths New Strategic Plan"
  (NOT-AT-20-014)
  National Center for Complementary and Integrative Health
  

• Notice of Interest in Advancing Research on FMR1-Associated Conditions
  (NOT-HD-20-009)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Center for Advancing Translational Sciences
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  

• Notice of NICHD Participation in NOT-EB-20-012 "Notice of Change in Application Due Date for PAR-19-215 Due to Public Health Emergency for United States Coronavirus Disease 2019 (COVID-19)"
  (NOT-HD-20-017)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

• Notice Announcing the Availability of Common Data Elements for Research Related to the Public Health Emergency caused by Coronavirus Disease 2019 (COVID-19)
  (NOT-MH-20-061)
  National Institute of Mental Health
  

• Findings of Research Misconduct
  (NOT-OD-20-113)
  National Institutes of Health
  

• Notice of Participation of the Environmental Influences on Child Health Outcomes (ECHO) in PA-18-591 "Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)"
  (NOT-OD-20-115)
  National Institutes of Health
  

• Notice of Participation of the Environmental Influences on Child Health Outcomes (ECHO) in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"
  (NOT-OD-20-116)
  National Institutes of Health
  

Notice of Changes to Funding Opportunities

• Notice of NIA Participation in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"
  (NOT-AG-20-036)
  National Institute on Aging
  

• Notice of NIDA Participation in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"
  (NOT-DA-20-061)
  National Institute on Drug Abuse
  

• Notice of NIDCD's Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"
  (NOT-DC-20-010)
  National Institute on Deafness and Other Communication Disorders
  

• Rescinding NOT-HG-20-041 NHGRI Late Application Policy for NHGRI-Specific FOAs with Application Due Dates in May, June, and July and Clarifying the Late Application Receipt Dates of NHGRI-Specific FOAs (NOT-HG-20-042)
  (NOT-HG-20-042)
  National Human Genome Research Institute
  

• Notice of Change in Application Due Date for RFA-HL-20-029 "Limited Competition: Small Grant Program for NHLBI K01/K08/K23 Recipients (R03 - Clinical Trial Optional)"
  (NOT-HL-20-794)
  National Heart, Lung, and Blood Institute
  

• Notice to Extend RFA-MH-20-505, Practice-Based Research for Implementing Scalable Evidence-Based Prevention Interventions in Primary Care Settings (R01 Clinical Trial Optional)
  (NOT-MH-20-059)
  National Institute of Mental Health
  

• Notice to Extend RFA-MH-20-506, "Practice-Based Research for Implementing Scalable Evidence-Based Prevention Interventions in Primary Care Settings (R34 Clinical Trial Required)"
  (NOT-MH-20-060)
  National Institute of Mental Health
  

• Notice of ORWH Participation in PA-20-135, Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement Clinical Trial Optional)
  (NOT-OD-20-111)
  Office of Research on Women's Health
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for INIA Administrative Resource (U24 Clinical Trial Not Allowed)
  (NOT-AA-20-014)
  National Institute on Alcohol Abuse and Alcoholism
  

• Notice of Intent to Publish a Funding Opportunity Announcement for INIA Research Resource (U24 Clinical Trial Not Allowed)
  (NOT-AA-20-015)
  National Institute on Alcohol Abuse and Alcoholism
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Community Interventions to Address the Consequences of the COVID-19 Pandemic for Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional)
  (NOT-MD-20-023)
  National Institute on Minority Health and Health Disparities
  National Center for Complementary and Integrative Health
  National Institute on Aging
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  National Institute of Nursing Research
  Office of Behavioral and Social Sciences Research
  Office of Disease Prevention
  Office of Research on Women's Health
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Digital healthcare interventions to address the secondary health effects related to social, behavioral, and economic impact of COVID-19 (R01 - Clinical Trial Optional)
  (NOT-MH-20-058)
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Nursing Research
  Office of Behavioral and Social Sciences Research
  Office of Disease Prevention
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Research on Co-morbid Substance Use, Substance Use Disorders, and Other Psychiatric Disorders
  (NOT-DA-20-004)
  National Institute on Drug Abuse
  Office of Research on Women's Health
  

• Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders
  (NOT-DC-20-008)
  National Institute on Deafness and Other Communication Disorders
  

• Notice of Special Interest (NOSI) of NIDCR in Supporting Dental, Oral, and Craniofacial Research Using Bioinformatic, Computational, and Data Science Approaches
  (NOT-DE-20-006)
  National Institute of Dental and Craniofacial Research
  

• Notice of Special Interest: NIGMS Priorities for Small Business Development of Sepsis Diagnostics and Therapeutics
  (NOT-GM-20-028)
  National Institute of General Medical Sciences
  

• Notice of Special Interest (NOSI): Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations
  (NOT-MD-20-022)
  National Institute on Minority Health and Health Disparities
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Heart, Lung, and Blood Institute
  National Institute on Alcohol Abuse and Alcoholism
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  Office of Behavioral and Social Sciences Research
  Office of Disease Prevention
  Office of Research on Women's Health
  

• Notice of Special Interest (NOSI): Chimerism in Marmosets and other New World Primates
  (NOT-MH-20-048)
  National Institute of Mental Health
  National Institute on Aging
  National Institute of Allergy and Infectious Diseases
  National Institute on Drug Abuse
  National Institute of Neurological Disorders and Stroke
  

• Notice of Special Interest (NOSI): Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19
  (NOT-MH-20-053)
  National Institute of Mental Health
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Heart, Lung, and Blood Institute
  National Institute on Alcohol Abuse and Alcoholism
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Nursing Research
  Office of Behavioral and Social Sciences Research
  Office of Disease Prevention
  Office of Research on Women's Health
  

Funding Opportunities

• Mid-Career Enhancement Awards to Integrate Basic Behavioral, Biomedical, and/or Social Scientific Processes (K18 No Independent Clinical Trials)
  (PAR-20-211)
  NIH Basic Behavioral and Social Science Opportunity Network
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): March 17, 2021, March 17, 2022, March 17, 2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  
  

• National Institute of General Medical Sciences Institutional Predoctoral Research Training Grant (T32 - Clinical Trial Not Allowed)
  (PAR-20-213)
  National Institute of General Medical Sciences
  Application Receipt Date(s): Standard dates apply All applications are due by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional)
  (PAR-20-221)
  National Institute on Drug Abuse
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
  
  

• Enhancing Science, Technology, EnginEering, and Math Educational Diversity (ESTEEMED) Research Education Experiences (R25)
  (PAR-20-223)
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): June 24, 2020; June 24, 2021; June 24, 2022
  
  

• Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional)
  (PAR-20-224)
  National Institute on Drug Abuse
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below
  
  

• Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)
  (PAR-20-225)
  National Institute on Drug Abuse
  Application Receipt Date(s): November 2, 2020, October 19, 2021, October 19, 2022 by 5:00 PM local time of applicant organization. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Mid-Career Enhancement Awards to Integrate Basic Behavioral, Biomedical, and/or Social Scientific Processes (K18 Basic Experimental Studies with Humans Required)
  (PAR-20-226)
  NIH Basic Behavioral and Social Science Opportunity Network
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): March 17, 2021, March 17, 2022, March 17, 2023, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  
  

• Alcohol-HIV/AIDS Program Project Comorbidities, Coinfections, and Complications Research: Intervention and Cross-Cutting Foundational Research (P01 Clinical Trial Optional)
  (RFA-AA-20-009)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date listed below.
  
  

• Emergency Awards: SARS-CoV-2 Serological Sciences Centers of Excellence (U54 Clinical Trial Optional)
  (RFA-CA-20-038)
  National Cancer Institute
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): July 22, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. No late applications will be accepted for this FOA.
  
  

• Emergency Awards: Research Projects in SARS-CoV-2 Serological Sciences (U01 Clinical Trial Optional)
  (RFA-CA-20-039)
  National Cancer Institute
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): July 22, 2020
  
  

• Advancing HIV/AIDS Research through Computational Neuroscience FOA (R01 - Clinical Trial Optional)
  (RFA-DA-21-013)
  National Institute on Drug Abuse
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
  
  

• George M. O'Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional)
  (RFA-DK-20-008)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): November 4, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Advancing Genomic Medicine Research (Clinical Trial Optional) (R01)
  (RFA-HG-20-036)
  National Human Genome Research Institute
  Application Receipt Date(s): August 3, 2020; March 8, 2021; November 2, 2021; August 1, 2022; March 13, 2023. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Advancing Genomic Medicine Research (Clinical Trial Optional) (R21)
  (RFA-HG-20-037)
  National Human Genome Research Institute
  Application Receipt Date(s): August 3, 2020; March 8, 2021; November 2, 2021; August 1, 2022; March 13, 2023. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 Clinical Trial Required)
  (RFA-HL-21-003)
  National Heart, Lung, and Blood Institute
  National Center for Advancing Translational Sciences
  National Eye Institute
  National Institute on Aging
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): October 2, 2020